- Home
- HNRG vs XNCR Comparison
HNRG vs XNCR Comparison
Compare HNRG & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HNRG
- XNCR
- Stock Information
- Founded
- HNRG 1949
- XNCR 1997
- Country
- HNRG United States
- XNCR United States
- Employees
- HNRG N/A
- XNCR N/A
- Industry
- HNRG Coal Mining
- XNCR Biotechnology: Pharmaceutical Preparations
- Sector
- HNRG Energy
- XNCR Health Care
- Exchange
- HNRG Nasdaq
- XNCR Nasdaq
- Market Cap
- HNRG 632.2M
- XNCR 579.3M
- IPO Year
- HNRG N/A
- XNCR 2013
- Fundamental
- Price
- HNRG $15.74
- XNCR $8.36
- Analyst Decision
- HNRG Strong Buy
- XNCR Buy
- Analyst Count
- HNRG 3
- XNCR 7
- Target Price
- HNRG $18.33
- XNCR $27.50
- AVG Volume (30 Days)
- HNRG 702.8K
- XNCR 811.3K
- Earning Date
- HNRG 08-05-2025
- XNCR 08-04-2025
- Dividend Yield
- HNRG N/A
- XNCR N/A
- EPS Growth
- HNRG N/A
- XNCR N/A
- EPS
- HNRG N/A
- XNCR N/A
- Revenue
- HNRG $410,607,000.00
- XNCR $127,228,000.00
- Revenue This Year
- HNRG N/A
- XNCR N/A
- Revenue Next Year
- HNRG $9.86
- XNCR $28.84
- P/E Ratio
- HNRG N/A
- XNCR N/A
- Revenue Growth
- HNRG N/A
- XNCR N/A
- 52 Week Low
- HNRG $4.86
- XNCR $7.16
- 52 Week High
- HNRG $19.71
- XNCR $27.24
- Technical
- Relative Strength Index (RSI)
- HNRG 47.94
- XNCR 45.32
- Support Level
- HNRG $15.11
- XNCR $7.65
- Resistance Level
- HNRG $16.10
- XNCR $8.80
- Average True Range (ATR)
- HNRG 0.68
- XNCR 0.52
- MACD
- HNRG -0.01
- XNCR -0.05
- Stochastic Oscillator
- HNRG 56.77
- XNCR 33.33
About HNRG Hallador Energy Company
Hallador Energy Co is a coal mining company with operations in Indiana, USA, and it is part of the electric power generation industry. The operations of the company are divided into two primary reportable segments, the Coal Operations and Electric Operations segments. The majority of revenue is earned from the Coal Operations segment.
About XNCR Xencor Inc.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.